Alnylam Gets Favorable Ruling in Patent Suit Against Tekmira

Alnylam Pharmaceuticals said a U.S. federal court has ruled that it could sue Canada’s Tekmira Pharmaceuticals for infringing patents on lipid nanoparticle technology exclusively licensed to Alnylam.
Reuters